Ailawadhi S, Sung K-W, Carlson L A, Baer M R
Department of Medicine, State University of New York, Buffalo, NY, USA.
J Clin Pharm Ther. 2007 Apr;32(2):199-202. doi: 10.1111/j.1365-2710.2007.00813.x.
To report a case of serotonin syndrome associated with interaction between fentanyl and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl.
A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl. Based on the Naranjo probability scale, serotonin syndrome was a probable adverse reaction associated with co-administration of citalopram and fentanyl.
Serotonin syndrome is a potentially lethal pharmacodynamic interaction between medications that increase serotonergic transmission at the synaptic junction. The development of new pharmacological agents with varied properties and actions has increased the risk of serotonin syndrome as a clinical diagnosis. SSRIs and fentanyl are commonly co-administered, especially in the setting of chronic or malignant pain, as underlying depression may contribute to the pathogenesis of pain.
Healthcare professionals should be aware of the possible development of serotonin syndrome as a complication of initiation of fentanyl and other phenylpiperidine opioids in patients treated with SSRIs.
报告一例由芬太尼与西酞普兰相互作用引发的血清素综合征病例,用药史、临床特征及停用芬太尼后的症状缓解情况均可证明。
一名长期服用选择性5-羟色胺再摄取抑制剂(SSRI)西酞普兰的65岁患者,在开始使用芬太尼后出现意识模糊、烦躁不安、心动过速、震颤、肌阵挛性抽搐及步态不稳等与血清素综合征相符的症状,停用芬太尼后所有症状和体征均消失。根据纳伦霍概率量表,血清素综合征是西酞普兰与芬太尼联合使用可能出现的不良反应。
血清素综合征是一种药物之间潜在致命的药效学相互作用,这些药物会增加突触连接处的5-羟色胺能传递。具有不同特性和作用的新药的出现增加了血清素综合征作为临床诊断的风险。SSRI类药物和芬太尼经常联合使用,尤其是在慢性或恶性疼痛的情况下,因为潜在的抑郁症可能导致疼痛的发病机制。
医疗保健专业人员应意识到,在接受SSRI治疗的患者中,开始使用芬太尼和其他苯基哌啶类阿片类药物可能会引发血清素综合征这一并发症。